Get the Stockscreener App
1.11
6.72%
-0.08
After Hours:
1.12
0.01
+0.90%
Standard Biotools Inc stock is traded at $1.11, with a volume of 2.00M.
It is down -6.72% in the last 24 hours and down -26.49% over the past month.
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. Its segments include Proteomics and Genomics. It generates maximum revenue from the Proteomics segment. Geographically, it derives a majority of its revenue from the Americas.
See More
Previous Close:
$1.19
Open:
$1.22
24h Volume:
2.00M
Relative Volume:
1.21
Market Cap:
$426.87M
Revenue:
$106.34M
Net Income/Loss:
$-74.66M
P/E Ratio:
-1.1684
EPS:
-0.95
Net Cash Flow:
$-46.12M
1W Performance:
-10.48%
1M Performance:
-26.49%
6M Performance:
-15.27%
1Y Performance:
-18.08%
1-Day Range:
$1.10
$1.22
1-Week Range:
$1.10
$1.295
52-Week Range:
$0.92
$1.72
Standard Biotools Inc Stock (LAB) Company Profile
Name
Standard Biotools Inc
Sector
Industry
Phone
(650) 266-6000
Address
2 TOWER PLACE, SOUTH SAN FRANCISCO
Compare LAB vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LAB
Standard Biotools Inc
|
1.11 | 457.63M | 106.34M | -74.66M | -46.12M | -0.95 |
|
ABT
Abbott Laboratories
|
111.47 | 197.52B | 44.33B | 6.48B | 6.92B | 3.7033 |
|
SYK
Stryker Corp
|
365.85 | 139.09B | 25.12B | 3.25B | 4.28B | 8.4018 |
|
MDT
Medtronic Plc
|
100.88 | 129.59B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
BSX
Boston Scientific Corp
|
74.12 | 108.96B | 20.08B | 2.89B | 3.82B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
76.44 | 46.04B | 6.07B | 1.06B | 799.60M | 1.8527 |
Standard Biotools Inc Stock (LAB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-13-25 | Downgrade | TD Cowen | Buy → Hold |
| Feb-27-25 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Apr-16-24 | Initiated | TD Cowen | Buy |
| Apr-04-24 | Initiated | Jefferies | Buy |
| Jul-12-23 | Initiated | KeyBanc Capital Markets | Overweight |
Standard Biotools Inc Stock (LAB) Latest News
Standard BioTools Inc.'s (NASDAQ:LAB) Popularity With Investors Under Threat As Stock Sinks 27% - simplywall.st
Standard BioTools to Announce Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026 - GlobeNewswire
Swing Trade: Will BayFirst Financial Corp benefit from geopolitical trends2025 Valuation Update & Weekly High Conviction Ideas - baoquankhu1.vn
Market Outlook: Can Standard BioTools Inc stock outperform in a bear market2025 Top Gainers & Free Safe Entry Trade Signal Reports - baoquankhu1.vn
Standard BioTools Strengthens Balance Sheet with Major Divestiture - AD HOC NEWS
Aug Patterns: Is Standard BioTools Inc impacted by rising ratesJuly 2025 Technicals & Weekly Market Pulse Alerts - baoquankhu1.vn
Market Pulse: Will Standard BioTools Inc stock recover after earnings2025 Momentum Check & Safe Entry Point Identification - baoquankhu1.vn
Illumina completes acquisition of SomaLogic - marketscreener.com
Weekly Earnings: How volatile is Standard BioTools Inc stockJuly 2025 Chart Watch & Daily Stock Momentum Reports - baoquankhu1.vn
Standard BioTools completes sale of SomaLogic to Illumina for $350 million - Investing.com Nigeria
Standard BioTools Inc. (LAB) Stock Analysis: Navigating Challenges with a 9.93% Potential Upside - DirectorsTalk Interviews
Standard BioTools (LAB) Concludes Sale of SomaLogic for $425 Mil - GuruFocus
Standard BioTools Completes Major Proteomics Business Divestiture - TipRanks
Standard BioTools Completes Sale of SomaLogic to Illumina - citybiz
Standard BioTools Inc. Completes $350 Million Sale of SomaLogic to Illumina, Enhancing Financial Position for Growth Strategy - Quiver Quantitative
Illumina (NASDAQ: ILMN) completes $350M SomaLogic proteomics deal - Stock Titan
Here's Why We're Not At All Concerned With Standard BioTools' (NASDAQ:LAB) Cash Burn Situation - simplywall.st
Aug Reactions: Is Paramount Global stock risky to hold now2025 Technical Patterns & Free Expert Verified Stock Movement Alerts - baoquankhu1.vn
Standard BioTools (NASDAQ:LAB) versus Clover Health Investments (NASDAQ:CLOV) Critical Review - Defense World
Chipmakers Recap: Can Standard BioTools Inc stock double in the next yearJuly 2025 Highlights & Low Risk Profit Maximizing Plans - baoquankhu1.vn
Aug Outlook: Will Standard BioTools Inc stock recover after earningsPortfolio Growth Summary & Fast Entry High Yield Tips - baoquankhu1.vn
Standard BioTools (NASDAQ:LAB) shareholders have endured a 76% loss from investing in the stock five years ago - Yahoo Finance
Death Cross: Is Sunshine Biopharma Incs ROE strong enoughEarnings Growth Report & Stock Portfolio Risk Management - baoquankhu1.vn
The Truth About SomaLogic Inc: Is This Quiet Biotech About To Blow Up Or Fade Out? - AD HOC NEWS
Sumitomo Mitsui Trust Group Inc. Sells 773,708 Shares of Standard BioTools Inc. $LAB - MarketBeat
SomaLogic Urges Stockholders to Maximize Value of Their Investment by Voting "FOR" Pending Merger with Standard BioTools - Intellectia AI
Standard BioTools Inc. (LAB) Stock Analysis: Navigating a Challenging Market with Innovative Technologies - DirectorsTalk Interviews
Sentiment Recap: Why Standard BioTools Inc stock could rally in 20252025 Growth vs Value & Trade Opportunity Analysis - Bộ Nội Vụ
Standard BioTools (NASDAQ:LAB) Trading 5.6% HigherStill a Buy? - MarketBeat
Illumina Announces Preliminary Unaudited Financial Results for Q4 and Fiscal Year 2025 - TradingView
Why Standard BioTools Inc. stock could outperform in 2025Market Growth Summary & AI Powered Market Trend Analysis - ulpravda.ru
Will Standard BioTools Inc. stock benefit from green energy trendsPortfolio Risk Report & Reliable Intraday Trade Alerts - Улправда
User | woonsocketcall.comStandard BioTools Inc.Common Stock (Nasdaq:LAB) Stock Quote - FinancialContent
Standard BioTools (LAB) Reports Q1 Loss, Tops Revenue Estimates - sharewise.com
Standard BioTools Announces Preliminary Fourth Quarter and Full Year 2025 Revenue - Sahm
Can Standard BioTools Inc. stock maintain operating marginsLayoff News & Expert-Curated Trade Recommendations - Улправда
Will Standard BioTools Inc. (FLB) stock rise with strong economyJuly 2025 Catalysts & Low Risk High Reward Ideas - Улправда
Is Standard BioTools Inc. stock a buy before product launchesMarket Risk Summary & High Accuracy Investment Signals - ulpravda.ru
Standard BioTools (NASDAQ:LAB) Shares Gap UpShould You Buy? - MarketBeat
Standard BioTools Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year 2025 - marketscreener.com
Standard BioTools Reports Preliminary Q4, Full-Year Revenue - Nasdaq
Standard BioTools (NASDAQ:LAB) & Hinge Health (NYSE:HNGE) Critical Contrast - Defense World
What analysts say about Standard BioTools Inc stockExit Strategy Tips & Investment Portfolio Recommendations - earlytimes.in
User | theeveningleader.comStandard BioTools Inc.Common Stock (Nasdaq:LAB) Stock Quote - markets.financialcontent.com
Further weakness as Standard BioTools (NASDAQ:LAB) drops 15% this week, taking five-year losses to 80% - simplywall.st
Standard BioTools: Outlook Still Murky (NASDAQ:LAB) - Seeking Alpha
Institutional owners may consider drastic measures as Standard BioTools Inc.'s (NASDAQ:LAB) recent US$96m drop adds to long-term losses - Yahoo Finance
Standard BioTools (NASDAQ:LAB) Stock Price Down 6.1% – Here’s Why - Defense World
Standard BioTools (NASDAQ:LAB) Stock Price Down 6.1%What's Next? - MarketBeat
What Standard BioTools Inc.'s (NASDAQ:LAB) 28% Share Price Gain Is Not Telling You - 富途牛牛
Standard BioTools (NASDAQ:LAB) Stock Price Down 3.9% – What’s Next? - Defense World
Standard Biotools Inc Stock (LAB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.45%
0.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):